MarketInOut Stock Screener Log In | Sign Up
 

Pelthos Therapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/23/2026
Pelthos Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization75 mln
Float1.72 mln
Earnings Date11/12/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

51.71
Transformational upside

Relative Strength

15 / 100
Significantly lagging

Pre-Tax Margin

-217%
Severely loss-making

ROE

-390
Deeply negative

Altman Z-Score

-2.29
Deeply distressed

Business Description

Pelthos Therapeutics Inc. is a Durham, North Carolina-based pharmaceutical company founded in 2002 that focuses on developing and selling treatments for skin conditions in both adults and children. Its approved products include therapies for molluscum contagiosum, impetigo, and head lice, covering patients from infancy onward. The company also owns a proprietary nitric oxide technology platform that supports its ongoing research efforts.

Key Fundamentals

EPS-27.53
ROE-390
RPS13.21
ROIC-69.85
ROA-79.92
Interest Cover-7.81
EBITDA, mln-81.06
EV / EBITDA-1.56
EV / EBIT-1.46
Revenue, mln43.30
EV / Revenue2.92

Quote Details

Last 17.00
Change -2.59 (-13.22%)
Open 19.59
Volume 57,780
Turnover 982,260
Average Volume 49,240

Financial Ratios

Pre-Tax Profit Margin-217
Current Ratio1.98
Price / Sales1.66

Financial Strength

Altman Z-Score-2.29
Piotroski F-Score 4 / 9
1-Year Target Price51.71
Short Ratio2.89
Short % of Float5.06

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -15.63% 5 / 100   
1 Month -24.11% 15 / 100   
2 Months -37.64% 13 / 100   
6 Months -26.28% 23 / 100   
1 Year -46.03% 19 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog